TW200616645A - Multiple sclerosis treatment - Google Patents

Multiple sclerosis treatment

Info

Publication number
TW200616645A
TW200616645A TW094131868A TW94131868A TW200616645A TW 200616645 A TW200616645 A TW 200616645A TW 094131868 A TW094131868 A TW 094131868A TW 94131868 A TW94131868 A TW 94131868A TW 200616645 A TW200616645 A TW 200616645A
Authority
TW
Taiwan
Prior art keywords
multiple sclerosis
bodies
exteriorly
mammal
liposomes
Prior art date
Application number
TW094131868A
Other languages
English (en)
Inventor
Marina Anetta Lynch
Yvonne Mairead Nolan
Anthony Ernest Bolton
Arkady Mandel
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of TW200616645A publication Critical patent/TW200616645A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094131868A 2004-09-15 2005-09-15 Multiple sclerosis treatment TW200616645A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE20040613 2004-09-15

Publications (1)

Publication Number Publication Date
TW200616645A true TW200616645A (en) 2006-06-01

Family

ID=35207670

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094131868A TW200616645A (en) 2004-09-15 2005-09-15 Multiple sclerosis treatment

Country Status (9)

Country Link
US (1) US20060105032A1 (zh)
EP (1) EP1793833A1 (zh)
AR (1) AR052642A1 (zh)
CA (1) CA2578248A1 (zh)
EA (1) EA200700626A1 (zh)
PE (1) PE20060661A1 (zh)
TW (1) TW200616645A (zh)
UY (1) UY29119A1 (zh)
WO (1) WO2006029886A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
AU2008232677B2 (en) 2007-03-29 2013-09-19 National Jewish Health Surfactant lipids, compositions thereof, and uses thereof
US8173115B2 (en) * 2008-07-29 2012-05-08 The Board Of Regents Of The University Of Texas System Particle compositions with a pre-selected cell internalization mode

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
IL155696A0 (en) * 2000-11-09 2003-11-23 Neopharm Inc Sn-38 lipid complexes and methods of use
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response

Also Published As

Publication number Publication date
EP1793833A1 (en) 2007-06-13
UY29119A1 (es) 2006-05-31
AR052642A1 (es) 2007-03-28
WO2006029886A1 (en) 2006-03-23
PE20060661A1 (es) 2006-09-16
EA200700626A1 (ru) 2007-10-26
US20060105032A1 (en) 2006-05-18
CA2578248A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
TW200602088A (en) Treatment of age-related memory impairment
NZ596420A (en) Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
EE200300029A (et) Fosfonaatnukleotiidanaloogide eelravimid ning meetodid nende valimiseks ning valmistamiseks
CY1116768T1 (el) Συνθεσεις οι οποιες περιεχουν βλαστοκυτταρα θηλυκης γαμετικης σειρας και μεθοδοι χρησης αυτων
DE69941713D1 (de) Abstammungs-spezifische zellen und vorläuferzellen
WO2007068354A8 (en) Means and methods for the treatment of tumorous diseases
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
IL135068A0 (en) Stimulation of hematopoietic cells in vitro
CY1114073T1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
BRPI0514703A (pt) produção de polipeptìdeos
NZ593182A (en) Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
DE602006020335D1 (de) Verwendung von parp-1-hemmern
TW200616645A (en) Multiple sclerosis treatment
ATE376065T1 (de) Enzymatische herstellung urethangruppenhaltiger (meth)acrylsäureeester
WO2022217123A3 (en) Combination therapies with cbl-b inhibitor compounds
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
BRPI0514600A (pt) métodos para a fabricação de um composto, para a purificação de um composto, para o tratamento de um indivìduo tendo uma condição neoplástica, tendo carcinoma de célula escamosa, e tendo carcinoma de célula basal, para a redução ou prevenção da ocorrência de uma condição neoplástica em um indivìduo, e para a redução de triglicerìdeos no soro em um indivìduo, composto, e, composição farmacêutica
AU2003278667A1 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
BRPI0517132A (pt) regime de cladribina para o tratamento da esclerose múltipla
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
BR0311361A (pt) Atuador linear e dispositivos de bomba de ar e de compressor usando o atuador
MXPA06009711A (es) Uso de carboxipeptidasa g para combatir la toxicidad de antifolato.
Pohanka et al. Sulfur mustard induced oxidative stress and its alteration using asoxime (HI-6)
BR0313224A (pt) Composição farmacêutica contendo composto para terapia da disfunção sexual para ser administrada de modo oral que proporciona rápido inìcio de seus efeitos farmacológicos